Allergan plc (AGN) is an interesting player in the Healthcare space, with a focus on Drugs – Generic. The stock has been active on the tape, currently trading at $158.41, up from yesterday’s close by 0.72%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Allergan plc (AGN) currently trades with a market capitalization of $51.42 Billion. That value represents a market adjusting for revenues that have been growing by 11.95 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of $5.53 Billion over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $3.38 on a per share basis this quarter. Perhaps, that suggests something about why 0.66% of the outstanding share supply is held by institutional investors.
We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Allergan plc recorded a 52-week high of $256.80. It is now trading 98.39% off that level. The stock is trading $168.49 its 50-day moving average by 10.08%. The stock carved out a 52-week low down at $142.81.
In recent action, Allergan plc (AGN) has made a move of -2.68% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 17.8, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 3.24% with $324.59 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of AGN.